Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Orphan Designations For Pediatric Subgroups Of Common Diseases To End

Executive Summary

US FDA's draft guidance closes loophole where sponsors could obtain an orphan designation for a pediatric subset and then be exempt from requirements to conduct pediatric studies.

You may also be interested in...



Are Orphan Incentives Necessary For Development? Sponsors Aren't So Sure

Drug sponsors tell US GAO that orphan incentives don't draw them to the space, and several stakeholders say high prices and scientific discovery are the reason for the sector's growth.

Panel Of Former US FDA Commissioners Make Renewed Call For Independent Agency

Former FDA heads reflected on instances when they experienced pressure from their higher-ups; speakers also offered praise for the job Commissioner Scott Gottlieb is doing at the agency. 

Orphan Drug Policy Changes To Be Considered Under US FDA's FY 2019 Budget Proposal

Proposed $20m funding boost for rare disease development includes review of orphan incentives, including how to potentially stimulate development in ultra-orphan diseases.

Related Content

Topics

UsernamePublicRestriction

Register

PS122181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel